Dementia Alzheimer's type
Not recruitingStudy on the Safety and Effects of NPI-001 (Acetylcysteine Amide) for Patients Aged 50-85 with Mild Cognitive Impairment or Mild Alzheimer's Disease
Study on the Safety and Effects of NPI-001 (Acetylcysteine Amide) for Patients Aged 50-85 with Mild Cognitive Impairment or Mild Alzheimer's Disease
- Disease:Dementia Alzheimer's type
- Substances:Acetylcysteine Amide
Denmark- Participants:18–64 years · 65+ years
- Substances:Acetylcysteine Amide
- Sponsor:Arctic Therapeutics hf.












